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Background: Bovine viral diarrhea virus (BVDV) infections are endemic in cattle populations worldwide and cause
major economic losses. Thus, an effective vaccine is needed against the transmission of BVDV. The glycoprotein Erns
is one of the envelope proteins of this virus and shows BVDV-related immunogenicity. Here, we report the use
of Panax ginseng as an alternative production platform for the expression of glycoprotein Erns via Agrobacterium-
mediated transformation.
Result: Polymerase chain reaction (PCR) and reverse transcription (RT)-PCR analyses showed that pBI121-Erns was
stably integrated into the chromosome of transformants. ELISA assay and Western blot analysis confirmed the
antigenicity of plant-derived Erns glycoprotein. Immunogenicity was evaluated subcutaneously in deer using a
soluble protein extract of dried transgenic ginseng hairy roots. Specific humoral and cell-mediated immune responses
against BVDV were detected following immunization.
Conclusion: These results demonstrated that the Erns glycoprotein could be expressed in ginseng hairy roots and that
plant-derived glycoprotein Erns retained its antigenicity and immunogenicity.
Keywords: Bovine viral diarrhea virus, Transgenic ginseng vaccine, ErnsIntroduction
Bovine viral diarrhea virus (BVDV) is a positive-stranded
RNA virus of the Flaviviridae family [1,2] and an import-
ant cause of economic loss in herds worldwide. BVDV
infections can have several consequences such as acute
infection, diarrhea, fertility problems, and fatal mucosal
diseases, the incidences of which have been rising in re-
cent years [3,4]. Some reports have demonstrated that
BVDV infection could damage the immune system of
the infected animals and make them more susceptible to
other diseases. In addition, BVDV can be transmitted be-
tween a variety of animals such as cattle, sheep, and
whitetail deer [5-8] and the presence of BVDV in other
domestic species might be relevant to its epidemiology
[9]. It has been reported that BVDV infection rates in
young deer reached 60% ~ 86.7% in some areas of China
[10], which caused economic losses in the sika deer in-
dustry due to the high mortality and fetal infections as-
sociated with the disease. In our previous study, a new* Correspondence: lianxuezhang863@sina.com
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unless otherwise stated.single strain of BVDV, named CCSYD, was isolated and
verified from sika deer [11]. The BVDV infection in sika
deer is a serious concern and an effective strategy is
needed to fight against BVDV transmission.
Vaccines have been shown to be effective tools for use
in the eradication of economically important animal path-
ogens. There are several available commercial vaccines
against bovine viral diarrhea (BVD) but these show irregu-
lar performances. The low immunogenicity of inactivated
BVDV vaccines often leads to immune failure. Although
modified live vaccines provide certain protection against
homologous strains, the intrinsic risk of virulence rever-
sion remains a concern [12,13]. Thus, the use of recom-
binant subunit vaccines has been proposed as an
alternative to overcome these difficulties [14].
BVDV genomes are translated and processed into
eleven mature proteins which include a capsid protein
(C), one N-terminal protease (Npro), three envelope gly-
coproteins (E1, E2, and Erns), a protein of 7 kDa (p7),
and five non-structural proteins (NS2-3, NS4A, NS4B,
NS5A, and NS5B). After infection or vaccination, cattle
produce antibodies against the three envelope proteins
(E1, E2, and Erns) and against a non-structural proteinis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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neutralizing antibodies in BVDV-infected hosts [16,17].
However, the highly variable sequence of the E2 protein
often leads to immunization failure [18,19].
The Erns glycoprotein is one of the virus structural
proteins. Several studies have indicated that some of the
immunologically relevant Erns epitopes are conserved
among different BVDV isolates, and few differences are
found in Erns amino acid composition among different
pestiviruses [20,21]. As a conserved protein, BVDV Erns
has been used as an antigen for the serological detection
of BVDV [22]. BVDV Erns expressed in prokaryotic sys-
tems also produces neutralizing antibodies; however,
they are produced at low titers that are unable to effi-
ciently neutralize the virus. This was attributed to the
misfolding of Erns when expressed in prokaryotes [23].
Because eukaryotic expression can maintain correct
folding and glycosylation of proteins, eukaryotic expres-
sion has become a research focus in the study of subunit
vaccines. In our previous study, Gao et al. [24] successfully
constructed a prokaryotic expression vector PVAX1-E0
and confirmed that the recombined PVAX1-E0 could
produce specific humoral and cellular immune re-
sponses in rabbits. However, the subunit vaccines only
offered short-term immunity. Transgenic plants are
new eukaryotic expression-delivery systems that have
become attractive bioreactors in the production of
high-value medical peptides and proteins [25]. Plant-
based vaccines offer several advantages over traditional
vaccines such as ease of delivery, mucosal efficacy,
safety, rapid scalability, and low cost. To date, several
plant species have been used as antigen-delivery systems
for subunit vaccines [26,27]. For example, truncated glyco-
protein BVDV E2 has been expressed in Nicotiana taba-
cum leaves and subsequently showed high reactivity in
virus neutralization tests [28].Figure 1 Genetic identification of transgenic ginseng hairy roots. Genomic
(A) and RT-PCR (B) identification. DNA gel blot analysis was used to detect
3, 4, 5, and 6 show the Erns gene fragments (total genomic DNAs extracted
negative control (total genomic DNAs extracted from the leaves of differen
control by using pBI121-Erns plasmid DNA as PCR template and lane 7 show
product from untransformed ginseng. Lane 2: PCR product from pBI121-Ern
hairy roots. Lane 5: DNA molecular mass marker.Another way to improve the immune activity of vac-
cines is the use of an adjuvant. Vaccine adjuvants can
stimulate the immune system to increase the specific
antibody response. Panax ginseng C.A. Meyer, com-
monly known as ginseng, has been used as a medicinal
plant in East Asia for over 2000 years [29,30]. The major
function of ginseng is the stimulation of natural resist-
ance against infections [31]. Recently, research has
shown that extracts of ginseng can exert a number of
effects on the immune system such as improvement of
the phagocytic activity of macrophages, lymphocyte pro-
liferation enhancement, cytokine production stimulation,
and increased activity of neutrophils, CD4+ T cells, and
natural killer cells [32-34].
Results
Genetic analysis of transformed plants
Transgenic ginseng hairy roots were successfully ob-
tained. After the isolation of genomic DNA and total
RNA from transgenic hairy roots, 706 bp long bands
were detected using polymerase chain reaction (PCR)
and reverse transcription (RT)-PCR in all ginseng hairy
roots except in the negative control groups, which con-
firmed the stable integration of the expression vector
pBI121-Erns into the chromosome of the transformants
(Figure 1A and B).
Erns protein expression in transgenic ginseng hairy roots
To determine whether Erns protein was expressed in trans-
genic ginseng hairy roots, first, enzyme-linked immuno-
sorbent assay (ELISA) was carried out to detect the
antigen presence in the total soluble proteins from trans-
genic ginseng hairy roots. The result showed that the sol-
uble proteins from the transgenic group had immune
reactivity against anti-BVDV antiserum and the OD490
values of the transgenic groups were significantly higherDNA and total RNA were extracted from regenerated seedling for PCR
the pBI121-Erns transgene in transgenic ginseng hairy roots. (A) Lanes
from the leaves of different transgenic ginseng plants). Lane 1 is a
t untransformed wild-type ginseng plants). Lane 2 shows the positive
s the molecular mass markers. (B) RT-PCR analysis. Lane 1: RT-PCR
s plasmid. Lanes 3–4: RT-PCR product from different transgenic ginseng
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plied that Erns protein was expressed and accumulated in
transgenic Panax ginseng.
To further confirm the immunogenicity of the soluble
proteins from the transgenic group against anti-BVDV
antiserum, Western blot analysis was carried out. The re-
sult showed that a specific signal was detected in the total
soluble proteins from the selected transgenic plants after
immunoblotting with anti-BVDV antiserum (Figure 2B),
while no signal was observed in the untransformed
groups. The result further confirmed that the Erns proteins
expressed in transgenic ginseng hairy roots were immuno-
reactive to anti-BVDV antiserum.
Detection of deer serum antibody and cellular
immune level
Serum samples were used to evaluate antibody levels
of immunized deer. As shown in Figure 3, the OD
values increased with time after immunization in all
vaccinated groups, except in the control groups
(groups 2 and 5). Antibody level from groups 3 and 4
increased continuously, rising to an apex 11 days afterFigure 2 Protein expression analysis in transgenic Panax ginseng extract. (A
from transgenic ginseng hairy roots. The ELISA protocol is described in the M
from transgenic ginseng hairy roots. Lane 2: positive control (Erns protein expr
(proteins extracted from untransformed ginseng hairy roots). a–b The differenc
ginseng hairy roots) and other groups is significant (P < 0.05). The result show
reactivity against anti-BVDV antiserum and the OD490 values of the transgenic
(B) Western blot analysis showing the immune activity of Erns protein express
group (Lane 1) and the positive control [Lane 3, Erns protein expressed in bab
Lane 2, negative control (proteins extracted from untransformed ginseng hairthe second inoculation. Vaccinated animals from group
1 showed high antibody level which reached a peak
18 days after the second inoculation. No significant in-
creases in antibody level were detected in the negative
control groups (P > 0.05). The result revealed that the
transgenic plant vaccine (group 1) could produce a
specific humoral immune response in deer.
The sera collected at the time of immunization and
on 42 days post-immunization were used to detect
cell-mediated immune responses. The results showed
that there was a significant improvement in lympho-
cyte proliferation in the group treated with the trans-
genic hairy roots vaccine, inactivated BVDV vaccine,
and inactivated BVDV vaccine group + untransformed
ginseng hairy roots extract upon restimulation with
BVDV antigens (Figure 4). No specific proliferation
was detected in the control groups (groups 2 and 5)
(Figure 4). These results refer to phytohemagglutinin
(PHA)-induced lymphocyte proliferation and suggested
that Erns protein expressed in transgenic ginseng hairy
roots could prolong cell-mediated immune responses
against BVDV antigens.) ELISA was used to determine the presence of antigen Erns in extracts
aterials and methods section. Lane 1: recombinant proteins extracted
essed in baby hamster kidney (BHK)-21 cells. Lane 3: negative control
e between the negative control (proteins extracted from untransformed
ed that the soluble proteins from the transgenic group had immune
groups were significantly higher than those of the negative controls.
ed in transgenic ginseng hairy roots. In the transgenic ginseng hairy roots
y hamster kidney (BHK)-21 cells] a specific band of 50 kDa was detected.
y roots).
Figure 3 Specific humoral response in deer following vaccination. Specific humoral response in deer following vaccination. The deers were
immunized subcutaneously with an aqueous extract of transgenic ginseng hairy roots (group 1), an aqueous extract of untransformed ginseng
hairy roots (group 2), inactivated BVDV vaccine (group 3), inactivated BVDV vaccine and untransformed ginseng hairy roots extract (group 4),
and saline (group 5). Serum samples used to assess the presence of BVDV specific antibody were collected on days 0, 7, 14, 21, 28, 35, and 42
after primary immunization and detected at 490 nm. The OD values increased with time after immunization in all vaccinated groups, except in
the control groups (groups 2 and 5). The result reveals that the transgenic plant vaccine (group 1) could produce a specific humoral immune
response in deer. a–b The difference between the negative control (group 5) and other groups is significant (P < 0.05).
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Developing effective and inexpensive vaccines is vital for
the protection of animals against various infectious dis-
eases, particularly those that are highly transmissible.
Owing to the development of genetic molecular biology
and plant biotechnology, plants have emerged as a new
platform for the production and delivery of antigen proteins
in the form of plant-based vaccines. Using plant expression
systems to produce vaccines offers several advantages over
mammalian cells and yeast systems such as easy storage
and transportation, low cost, and enhanced safety because
the risks associated with human pathogen contamination
and needle-based delivery are avoided. Vaccines produced
in crop plants, when administered orally, can elicit both
systemic and mucosal protective immunities.
Panax ginseng C.A. Meyer, known for a thousand
years, has long been used as a valuable traditional Chin-
ese medicine. It has been reported that ginseng containsFigure 4 Lymphocyte blastogenesis assay. Blood was collected from deer on
Group 2: untransformed ginseng vaccine. Group 3: inactivated BVDV vaccine.
negative control. The result showed that there was a significant improvemen
hairy roots vaccine and suggested that Erns protein expressed in transgenic gi
BVDV antigens. a–b The difference between the negative control (group 5) anmany biologically active components such as ginseno-
sides, polyacetylenes, acidic polysaccharides, ginseng
proteins, and phenolic compounds [35]. Ginsenosides
and polyacetylenes are the primary components of Asian
ginseng. Some reports have indicated that ginsenosides
and polyacetylenes show high immunoregulatory activity
[36] while other investigations have also demonstrated
that using ginseng as a vaccine adjuvant can stimulate
the immune system to exert an increased specific anti-
body response [37].
However, there are still no reports regarding the use of
ginseng as a platform for antigen expression. As a peren-
nial herb, Panax ginseng is difficult to regenerate quickly
and genetically transform. In this study, we have suc-
cessfully induced the production of transgenic ginseng
hairy roots with Agrobacterium rhizogenes containing
the Erns gene. The glycoprotein Erns was expressed and
accumulated in transgenic ginseng hairy roots. Ginsengthe 42nd day after immunization. Group 1: transgenic ginseng vaccine.
Group 4: inactivated BVDV + untransformed ginseng vaccine. Group 5:
t in lymphocyte proliferation in the group treated with the transgenic
nseng hairy roots could prolong cell-mediated immune responses against
d other groups is significant (P < 0.05).
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the immune activity of the Erns subunit vaccine. Further-
more, plant-derived glycoprotein Erns has the ability to
generate an immune response in sika deer. This study
provides a new method by which a protein with weak im-
munogenicity can be used as a transgenic plant vaccine.
Materials and methods
Equipment and materials
The plasmid pBI121-Erns and Agrobacterium rhizogenes
A4 strains were provided by our laboratory. Restriction
enzymes, Taq DNA polymerase, TriPure Kit, and T4 ligase
were purchased from TaKaRa Biotechnology Co. (Dalian,
China) and used to construct the recombinant plasmid
pBI121-Erns. Ginseng (Panax ginseng C.A. Meyer) was
cultured in the Jilin Agricultural University (China).
Ethics statement
All deer were obtained from the DongDa Deer Industry
Co., Ltd. Deer care and maintenance was carried out at
the sika deer farm of the Jilin Agricultural University
and permission to undertake this work was granted by
the Management Bureau of Animal Husbandry in Jilin
Province (Shaoxian Liu, Director). All deer were main-
tained as per the directive rules of raising sika deer
(2012) and were approved by DongDa Deer Industry
Co., Ltd. Animal welfare and experimental procedures
were carried out in accordance with the Protocol Guide
GB/T 14926.50-2001, which was approved by the
Standardization Administration of the People’s Republic
of China. The research was also approved by the animal
ethics committees of the Jilin Agriculture University and
the National Deer Industry Association of China Animal
Agriculture Association (CAAA). All deer were anesthe-
tized prior to sampling. The blood samplings were per-
formed by veterinarians, biologists, or technicians with
previous training and experience in these procedures.
We collected up to 2 mL of blood via the jugular vein.
All surgery was performed under sodium pentobarbital
sedation and all efforts were made to minimize suffering.
Finally, none of the deer were sacrificed.
Plasmid construction
Total RNA from MDBK cells infected with the CCSYD
BVDV strain (belonging to BVDV 1b) was isolated and
reverse transcription was performed using hexa-random
primers (Biodynamics SRL, Argentina). The Erns open
reading frame was amplified using the forward primer
(5’-CCG GAT CCA TGG AAA ACA TAA CAC AGT
GG-3’, BamHI site underlined) and the reverse primer
(5’-GCG AGC TCT TAA GCG TAT GCT CCA AAC
CAC GT-3’ , SacІ site underlined). The PCR product was
digested with BamHI and SacІ and inserted into the
plant expression vector pBI121, which was digested withthe same enzymes to finally create the recombinant
plasmid pBI121-Erns. The obtained recombinant vector
was introduced into Agrobacterium rhizogenes A4 strain
by electroporation using the procedure previously
described [38].
Cultivation of Agrobacterium rhizogenes A4 strain
Agrobacterium rhizogenes A4 strain cells containing
pBI121-Erns were added to YEB solid culture medium
and activated three times at 27°C. A single colony iso-
lated from the Petri dish was then inoculated into 25 mL
YEB liquid culture medium and grown overnight at 27°C
shaking at 110 r min−1.
Preparation of explants
The rhizomes of two-year old ginsengs were thoroughly
cleaned with running tap water for 1–2 h, surface steril-
ized, and then disinfected by a brief rinse (30 s) in 75%
ethanol (v/v). The cleaned explants were finally treated
with HgCl2 (0.1%) for 6–8 min under aseptic conditions
and washed 5 times with sterile distilled water to remove
traces of HgCl2. Then, the sterile rhizomes were cut into
2–3 mm slices and cultured on Murashige and Skoog
(MS) medium for 2 days before the transformation
experiments.
Transformation procedure
Agrobacterium rhizogenes-mediated transformation was
carried out as described in our previous study [39]. After
cultivation for one or two months, roots started to appear
at the infection sites and single roots were subsequently
picked out and placed on fresh MS media with kanamycin
(500 mg L−1) to eliminate any bacteria. Hairy roots with
no bacterial contamination were cultured on hormone-
free half-strength MS solid medium in the dark at 26°C.
Hairy root lines were sub-cultured at 4 week intervals.
Transgenic hairy roots of Panax ginseng were verified by
PCR and RT-PCR using the forward primer 5’-CCG GAT
CCA TGG AAA ACA TAA CAC AGT GG-3’ and the re-
verse primer 5’-GCG AGC TCT TAA GCG TAT GCT
CCA AAC CAC GT-3’. Ginseng explants were also infil-
trated with a wild-type Agrobacterium rhizogenes A4
strain to obtain negative controls.
Protein extraction
Protein isolation was conducted using 0.5 g transgenic
hairy roots that were quickly ground in liquid nitrogen.
The resulting powder was resuspended in 1 mL extrac-
tion buffer (125 mM Tris-Cl pH 6.8, 4 mol L−1 urea, 4%
SDS, and 5% β-mercaptoethanol) and the resulting mix-
ture centrifuged at 12,000 × g for 20 min at 4°C. The
protein concentration in 1 mL of the supernatant was
detected by the Bradford protein assay [40] using bovine
serum albumin (BSA) as a standard.
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ELISA was employed to detect the expression of glyco-
protein Erns in transgenic hairy roots [41]. Briefly, the
extracts were incubated in the ELISA plate at 4°C over-
night, followed by 3 washes with PBST, and blocking
with 10% horse serum for 1 h at 37°C. After another 3
washes with PBST, anti-BVDV antiserum (1:20 dilution)
was used as primary antibody. Then, the plates were
incubated for 1 h at 37°C with horseradish peroxidase
(HRP) conjugated rabbit anti-bovine IgG (1:5,000 dilution)
as secondary antibody. The reaction was stopped after
5 min with 2 M H2SO4 (50 μL well
−1) and the absorbance
was examined using an ELISA reader at 490 nm.
Western blot analysis
The soluble proteins prepared from control and trans-
genic plants were analyzed by Western blot as previously
described [41]. The extracted total soluble proteins from
fresh transgenic hairy roots were subjected to electro-
phoresis on 12% sodium dodecyl sulfate polyacrylamide
gel (SDS-PAGE) and transferred to a nitrocellulose
membrane (GE Healthcare, USA). Western blotting was
carried out using anti-BVDV antiserum (1:100 dilution)
and HRP-conjugated rabbit anti-bovine IgG (1:5,000 di-
lution, Southern Biotechnology, USA) as primary and
secondary antibodies, respectively. The signals were de-
veloped using a SuperSignal West Pio Luminol kit
(Pierce, Rockford, USA).
Immunization schedule
Forty healthy 1-month-old male sika deers were randomly
divided into 5 groups (8 deer per group). The air-dried
transgenic and untransformed ginseng hairy roots were
soaked in physiological saline solution for 24 h. Then, the
aqueous extracts were filtered through 0.22 μm micropor-
ous membranes for sterilization. Group 1 was immunized
subcutaneously (s.c.) with 1 mL aqueous extract from
transgenic ginseng hairy roots (equivalent to 0.1 g trans-
genic ginseng hairy roots). Group 2 was immunized s.c.
with 1 mL aqueous extract from untransfromed ginseng
hairy roots with the same dose as group 1. Group 3 was
immunized s.c. with 100 TCID50 (median tissue culture
infective dose) of inactivated BVDV vaccine (purchased
from Chinese Veterinary Drug Control Room), while
group 4 was immunized s.c. with 100 TCID50 of inacti-
vated BVDV vaccine and 1 mL aqueous extract from un-
transformed ginseng hairy roots (equivalent to 0.1 g
transgenic ginseng hairy roots). Group 5 was injected s.c.
with 1 mL saline as a negative control. The second
immunization was carried out in all groups on the 14th
day after the initial immunization. Blood samples were
collected at the time of immunization (day 0) and on the
7th, 14th, 21st, 28th, 35th, and 42nd day after the first
immunization.Determination of specific antibodies in immunized deer
Indirect ELISA was carried out to test the presence of
the specific antibody in the sera from immunized deer.
The blood taken from the sera from deer was diluted
(1:40) in coating buffer (pH 8.0) and added to microti-
ter plates (100 μL well−1). The microtiter plates were
incubated for 2 h at 37°C. After removing the liquid,
the plates were washed 3 times with PBST, and blocked
with 10% horse serum for 2 h at 37°C. Then, 100 μL of
soluble whole virus antigen (containing 100 μg viral
proteins) extracted from the C24V BVDV (purchased
from the China Institute of Veterinary Drug Control)
was added to the plates and incubated for 2 h at 37°C.
After this, plates were washed and blocked as men-
tioned above. The absorbance was examined using an
ELISA reader at 490 nm.
Lymphocyte blastogenesis assay
Peripheral blood mononuclear cells were isolated from
anti-coagulated jugular blood and the cell viability was
assessed with a trypan blue dye exclusion assay. A survival
rate >95% was considered for quantification. Cell suspen-
sions were placed into 96-well round-bottom plates at a
concentration of 5 × 106 cells well−1 (100 μL). Then, the
plates were incubated with or without BVDV (104 TCID50
well−1). The MTT method was carried out to detect cell
viability [41]. The absorbance was examined at 570 nm.
Statistical analysis
Multiple group comparisons were performed using one
way analysis of variance (ANOVA) followed by Tukey’s
test in order to detect intergroup differences. GraphPad
Prism software (Version 5.0; GraphPad Software, Inc.,
San Diego, CA) was used to perform the statistical ana-
lysis. A P-value of <0.05 was considered statistically
significant.
Conclusions
In summary, glycoprotein Erns of BVDV can be effect-
ively expressed in transgenic ginseng hairy roots and
used as an antigen source for a possible vaccine against
BVDV infection. Whether viral envelope proteins can
improve the biosynthesis and accumulation of other
kinds of secondary metabolites would be the subject of
future research, and studies to investigate these and
other aspects are currently underway in our laboratory.
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